Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

Rheumatology and Therapy - 2021
Luiza R Grazziotin1, Gillian Currie1, Marinka Twilt2, Maarten J. IJzerman3, Michelle M.A. Kip3, Hendrik Koffijberg3, Susanne M. Benseler2, Joost F. Swart4, Sebastiaan J. Vastert4, Nico Wulffraat4, Rae S. M. Yeung5, Nicole Johnson2, Nadia Luca2, Päivi Miettunen6, Heinrike Schmeling2, Deborah Marshall2, Ucan Cure consortia Ucan Can-Du
1Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Room 3C56, Health Research Innovation Centre, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada
2Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, AB, Canada
3Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, the Netherlands
4Department of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital / UMC Utrech, Utrecht, The Netherlands
5Departments of Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, Canada
6Section of Rheumatology, Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Tóm tắt

Từ khóa


Tài liệu tham khảo

Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49.

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.

Shiff NJ, Lix LM, Oen K, et al. Chronic inflammatory arthritis prevalence estimates for children and adolescents in three Canadian provinces. Rheumatol Int. 2015;35(2):345–50.

Kulas DT, Schanberg L. Juvenile idiopathic arthritis. Curr Opin Rheumatol. 2001;13(5):392–8.

McCann LJ, Wedderburn LR, Hasson N. Juvenile idiopathic arthritis. Arch Dis Child. 2006;91(2):ep29–ep36.

Mullick MS, Nahar JS, Haq SA. Psychiatric morbidity, stressors, impact, and burden in juvenile idiopathic arthritis. J Health Popul Nutr. 2005;23(2):142–9.

Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30(5):958–65.

Grazziotin LR, Currie G, Kip MMA, et al. Health state utility values in juvenile idiopathic arthritis: what is the evidence? Pharmacoeconomics. 2020;38(9):913–26.

Kip MMA, de Roock S, Currie G, et al. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Rev Pharmacoecon Outcomes Res. 2020;1–10. https://doi.org/10.1080/14737167.2021.1857241.

Prince FH, de Bekker-Grob EW, Twilt M, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology. 2011;50(6):1131–6.

Yucel IK, Seyahi E, Kasapcopur O, Arisoy N. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatol Int. 2012;32(7):1955–62.

Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17(5):31.

Kip MMA, Currie G, Marshall DA, et al. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatr Rheumatol Online J. 2019;17(1):20.

Kuhlmann A, Schmidt T, Treskova M, et al. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17:79–87.

Luca NJ, Burnett HF, Ungar WJ, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis. Arthritis Care Res. 2016;68(12):1803–11.

Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.

Shenoi S, Horneff G, Cidon M, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol. 2018;36(5):920–8.

Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44–8.

Shiff NJ, Oen K, Rabbani R, Lix LM. Validation of administrative case ascertainment algorithms for chronic childhood arthritis in Manitoba. Canada Rheumatol Int. 2017;37(9):1575–84.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.

Alberta Health, Health Analytics Branch, Overview of Administrative Health Datasets. 2017. https://open.alberta.ca/dataset/657ed26d-eb2c-4432-b9cb-0ca2158f165d/resource/38f47433-b33d-4d1e-b959-df312e9d9855/download/research-health-datasets.pdf. Accessed 5 Dec 2020.

Statistics Canada. Table 18-10-0004-08, Consumer Price Index, monthly, percentage change, not seasonally adjusted, Canada, provinces, Whitehorse and Yellowknife — Health and personal care. https://doi.org/10.25318/1810000401-eng. Accessed 22 Dec 2020.

Alberta Health, Health Analytics Branch. Interactive Health Data Application - Hospital Ambulatory Care Case Costing 2015. http://www.ahw.gov.ab.ca/IHDA_Retrieval/ShowMetaDataNotesServlet?1504. Accessed 8 Oct 2020.

Alberta Health Care Insurance Plan - Medical Price List: Alberta Government; 2020. https://open.alberta.ca/dataset/568f8505-2304-4ce2-882c-2bbbc314b739/resource/94892cea-00e5-4a2b-9633-42163def7ba6/download/health-somb-medical-price-list-2020-05.pdf. Accessed 8 Oct 2020.

Børty L, Brøndum R, Bøgsted M. ccostr: an R package for estimating mean costs with censored data. J Open Source Softw. 2019;4(41):1593.

Chen S, Rolfes J, Zhao H. Estimation of mean health care costs and incremental cost-effectiveness ratios with possibly censored data. Stand Genomic Sci. 2015;15(3):698–711.

Marshall DA, Benchimol EI, MacKenzie A, et al. Direct health-care costs for children diagnosed with genetic diseases are significantly higher than for children with other chronic diseases. Genet Med. 2019;21(5):1049–57.

Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187–207.

Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics. 1999;15(3):241–56.

van den Berg I, Kip MMA, Marshall DA, et al. Juvenile idiopathic arthritis is associated with considerable financial burden to society: results of a Dutch cost analysis. Value Health. 2019;22:S632.

Thông tin
Thông tin xuất bản

Rheumatology and Therapy

Thông tin tác giả